Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Predictions

buy
Inventiva SA

Start price
Target price
Perf. (%)
€6.02
27.10.22
-
27.10.23
-42.03%
28.10.23

Could be worthwhile Investment >10% per year
Carmat

Start price
Target price
Perf. (%)
€12.25
22.10.22
€10.00
22.10.23
-72.94%
23.10.23

Could be worthwhile Investment >10% per year
Valneva SE

Start price
Target price
Perf. (%)
€8.01
05.09.22
-
05.10.26
-57.57%
11.03.24

Probably not worthwhile Investment
Abivax S.A.

Start price
Target price
Perf. (%)
€8.30
02.09.22
€5.00
31.12.24
85.30%
08.05.23

Could be very worthwhile Investment >20% year
buy
Poxel S.A.

Start price
Target price
Perf. (%)
€2.49
20.08.22
-
20.08.23
-75.54%
07.06.23

Could be worthwhile Investment >10% per year
buy
Valneva SE

Start price
Target price
Perf. (%)
€10.23
09.08.22
€14.00
09.08.23
-46.91%
30.05.23

Small cyclical dependencies
Below average Marketposition
Few uniques
buy
Cellectis Nom.

Start price
Target price
Perf. (%)
€3.52
07.08.22
€3.80
07.08.23
-52.13%
08.08.23

Could be worthwhile Investment >10% per year
buy
Abivax S.A.

Start price
Target price
Perf. (%)
€9.10
04.08.22
-
04.08.23
81.32%
05.08.23

Could be very worthwhile Investment >20% year
Valneva SE

Start price
Target price
Perf. (%)
€9.82
21.07.22
-
21.07.23
-30.16%
22.07.23

Revenue growth >5% per year expected
Could be very worthwhile Investment >20% year
High valuation
Growths slower than the competition
buy
Carmat

Start price
Target price
Perf. (%)
€14.84
30.03.22
€18.00
30.03.23
-17.45%
22.10.22

Could be worthwhile Investment >10% per year
buy
Valneva SE

Start price
Target price
Perf. (%)
€15.60
30.03.22
-
30.03.23
-55.74%
20.11.22

Could be worthwhile Investment >10% per year
Very valuable balance sheet
Innate Pharma

Start price
Target price
Perf. (%)
€2.51
07.03.22
-
07.03.23
21.39%
08.03.23

Probably not worthwhile Investment
buy
Poxel S.A.

Start price
Target price
Perf. (%)
€3.04
20.02.22
€4.00
20.03.22
-11.39%
21.03.22

Could be worthwhile Investment >10% per year
buy
Poxel S.A.

Start price
Target price
Perf. (%)
€4.07
15.02.22
€5.00
15.03.22
-25.36%
20.02.22

Could be worthwhile Investment >10% per year
buy
Innate Pharma

Start price
Target price
Perf. (%)
€3.24
10.02.22
€3.80
10.02.23
-4.81%
11.02.23

Could be worthwhile Investment >10% per year
buy
Valneva SE

Start price
Target price
Perf. (%)
€15.03
05.02.22
€20.00
05.02.23
-57.41%
06.02.23

Revenue growth >5% per year expected
Differentiated customer and product portfolio
Good culture
Could be very worthwhile Investment >20% year
buy
Innate Pharma

Start price
Target price
Perf. (%)
€3.51
01.02.22
€4.15
01.02.23
-7.69%
10.02.22

Could be worthwhile Investment >10% per year
buy
Valneva SE

Start price
Target price
Perf. (%)
€15.90
23.01.22
-
23.01.23
-5.47%
06.02.22

Could be very worthwhile Investment >20% year
buy
Innate Pharma

Start price
Target price
Perf. (%)
€4.12
10.01.22
-
10.01.23
-14.85%
01.02.22

Could be worthwhile Investment >10% per year
buy
Valneva SE

Start price
Target price
Perf. (%)
€19.03
04.01.22
-
04.01.23
-7.46%
07.01.22

Risky Investment
Edap Tms S.A. ADR

Start price
Target price
Perf. (%)
€5.00
03.01.22
-
03.01.23
27.00%
15.05.22

Probably not worthwhile Investment
buy
Quantum Genomics S.A.

Start price
Target price
Perf. (%)
€4.32
31.12.21
€5.00
31.12.22
-97.78%
01.01.23

Could be worthwhile Investment >10% per year
buy
Valneva SE

Start price
Target price
Perf. (%)
€24.64
16.12.21
€33.00
31.12.23
-67.02%
07.09.22

Could be very worthwhile Investment >20% year
buy
Valneva SE

Start price
Target price
Perf. (%)
€23.36
12.12.21
-
12.12.22
8.73%
25.12.21

Could be very worthwhile Investment >20% year
buy
Valneva SE

Start price
Target price
Perf. (%)
€23.36
11.12.21
€30.00
11.12.22
8.73%
25.12.21

Fair valuation
Very Future proof/growth oriented business model
Could be very worthwhile Investment >20% year
Higher risks for its business